Source: Annual Congress 2010 - Sarcoidosis: genes and mechanisms
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Sanderson, H. Lockstone, N. Kulakova, D. Baban, A. Leonard, A. McMichael, L. P. Ho (Oxford, , St-Leonard-by-Sea, United Kingdom). Gene-set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Eur Respir J 2010; 36: Suppl. 54, 3432

Member's Comments

No comment yet.

Related content which might interest you: First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Morphologic evaluation of lung in a scleroderma-like rabbit model Source: Annual Congress 2006 - Systemic diseases, environmental and genetic factors in interstitial lung disease Year: 2006 Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Biomarker discovery in chronic obstructive pulmonary disease (COPD) using epithelial lining fluid: A proteomic approach Source: Annual Congress 2011 - Phenotyping airway diseases Year: 2011 Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin Source: Eur Respir J 2001; 18: 17S-29S Year: 2001 BALF proteomic analysis in polymyositis/dermatomyositis patients with interstitial lung disease Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Molecular mechanisms of lung tissue remodeling in progression of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 Contribute of BAL proteomic analysis in sarcoidosis (S) and in idiopathic pulmonary fibrosis (IPF/UIP) Source: Eur Respir J 2006; 28: Suppl. 50, 564s Year: 2006 Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and human donor lungs Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis Source: Eur Respir J 2016; 48: 1612-1621 Year: 2016 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF pathogenesis Year: 2015